The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Abstract Background Tyrosine kinase inhibitor (TKI) therapy improves the overall survival of patients with chronic myeloid leukemia (CML). However, the risk of vascular adverse events (VAEs) in these patients is reported to be higher than that in healthy individuals, because of both CML itself and t...

Full description

Saved in:
Bibliographic Details
Main Authors: Naoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomonori Nakazato, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Katsuhiro Miura, Tatsuya Kawaguchi
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardio-Oncology
Online Access:https://doi.org/10.1186/s40959-025-00366-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items